Literature DB >> 6615816

Kinetics of bovine milk lipoprotein lipase and the mechanism of enzyme activation by apolipoprotein C-II.

I Posner, C S Wang, W J McConathy.   

Abstract

The kinetics of bovine milk lipoprotein lipase (LPL) were studied in order to determine the reaction mechanism of this enzyme. Reaction velocities were determined at varying concentrations of emulsified trioleoylglycerol (TG) and different fixed concentrations of apolipoprotein C-II (C-II) or at varying C-II concentrations and different fixed concentrations of TG. Neither the apparent Km(TG) nor the apparent Km(C-II) was affected by varying the concentrations of C-II or TG, respectively. However, C-II increased the apparent Vmax for the enzyme about 20-fold. The following kinetic parameters were calculated from Lineweaver-Burk plots: Km(C-II) = 2.5 X 10(-8) M and Km (TG) = 2.5 X 10(-3) M. The dissociation constant (KS) of the enzyme-TG binary complex was determined from Scatchard plots to be 7.6 X 10(-8) M. Heparin was found to be a competitive dead-end inhibitor against both TG and C-II. Tricapryloylglycerol represented a competitive inhibitor against TG but a noncompetitive inhibitor against C-II. C-II was shown to interact with dansylated bovine milk LPL, increasing its fluorescent emission by inducing a conformational change in the enzyme. Based on these studies, it was concluded that the LPL-catalyzed reaction follows a random, bireactant, rapid-equilibrium mechanism and the role of C-II in the activation process involves an increase in the catalytic rate constant (Kp) resulting from conformational changes of LPL induced by C-II.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6615816     DOI: 10.1021/bi00286a008

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  6 in total

1.  VLDL substrate properties and efficiency of their metabolic transformation by LPL.

Authors:  A D Dergunov; V V Shuvaev; N V Perova
Journal:  Experientia       Date:  1989-05-15

2.  C-terminal domain of apolipoprotein CII as both activator and competitive inhibitor of lipoprotein lipase.

Authors:  Q Cheng; P Blackett; K W Jackson; W J McConathy; C S Wang
Journal:  Biochem J       Date:  1990-07-15       Impact factor: 3.857

3.  Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III.

Authors:  C S Wang; W J McConathy; H U Kloer; P Alaupovic
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

4.  Acyl-chain specificity of human milk bile-salt-activated lipase.

Authors:  C S Wang
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

5.  Post-heparin LPL activity measurement using VLDL as a substrate: a new robust method for routine assessment of plasma triglyceride lipolysis defects.

Authors:  Mathilde Di Filippo; Christophe Marçais; Sybil Charrière; Oriane Marmontel; Martine Broyer; Mireille Delay; Micheline Merlin; Axel Nollace; René Valéro; Michel Lagarde; Valérie Pruneta-Deloche; Philippe Moulin; Agnès Sassolas
Journal:  PLoS One       Date:  2014-05-02       Impact factor: 3.240

Review 6.  Review of preventative HIV vaccine clinical trials in South Africa.

Authors:  Fatima Laher; Linda-Gail Bekker; Nigel Garrett; Erica M Lazarus; Glenda E Gray
Journal:  Arch Virol       Date:  2020-08-14       Impact factor: 2.574

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.